Artery Research
Volume 1, Issue 1 , Pages 13-19 , June 2007

Reducing arterial stiffness and wave reflection – Quest for the Holy Grail?

  • Azra Mahmud

      Affiliations

    • Corresponding Author InformationTel.: +353 1 8962667; fax: +353 1 4539033.

References 

  1. Nichols WW, O'Rourke MF. Theoretical experimental and clinical principles. McDonald's blood flow in arteries. London: Edward Arnold; 1998;p. 54–113
  2. Mahmud A, Feely J. Antihypertensive drugs and arterial stiffness. Expert Rev Cardiovasc Ther. 2003;1(1):89–102
  3. Mahmud A, Feely J. Augmentation index and pulse wave velocity: do both measure arterial stiffness?. Am J Hypertens. 2006;18(5):17A
  4. Mahmud A, Feely J. Doxazocin reduces augmentation index but not pulse wave velocity in essential hypertension. Br J Clin Pharmacol. 2006;61(5):628
  5. O'Rourke MF, Adji A. An updated clinical primer on large artery mechanics: implications of pulse waveform analysis and arterial tonometry. Curr Opin Cardiol. 2005;20:275–281
  6. Mahmud A, Feely J. Effect of angiotensin II receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens. 2002;15(12):1092–1095
  7. Safar ME, Thuilliez C, Richard V, Benetos A. Pressure-independent contribution of sodium to large artery structure and function in hypertension. Cardiovasc Res. 2000;46:269–276
  8. Benetos A, Lafleche A, Asmar R, Gautier S, Safar A, Safar ME. Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension. J Hum Hypertens. 1996;10:77–82
  9. Chen CH, Ting C-T, Lin SJ, Hsu TL, Yin ICP, Siu CO. Different effects of fosinopril and atenolol on wave reflection in hypertension patients. Hypertension. 1995;25:1034–1041
  10. Asmar RG, London GM, O'Rourke ME, Safar ME, REASON Project Co-ordinators and Investigators . Improvement in blood pressure, arterial stiffness and wave reflections with a very low dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001;38(4):922–926
  11. Kelly RP, Daley J, Avolio A, O'Rourke MF. Arterial dilatation and reduced wave reflection: benefit of dilevalol in hypertension. Hypertension. 1989;14:14–21
  12. Mahmud A, Feely J. Beta-blockers, nebivolol and atenolol favourable reduce arterial stiffness. J Hypertens. 2002;20(Suppl. 4):S376
  13. Fitchett D, Simkus GJ, Beaudry J, Marpole D. Reflected pressure waves on the ascending aorta: effect of glyceryl trinitrate. Cardiovasc Res. 1988;22:494–500
  14. Jiang XJ, O'Rourke MF, Jin WQ, Liu LS, Li CW, Tai PC, et al. Quantification of glyceryl trinitrate effect through analysis of the synthesised ascending aortic pressure waveform. Heart. 2002;88(2):143–148
  15. Mahmud A, Hennessy M, Feely J. Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens. 2001;15(10):707–713
  16. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932–943
  17. Mahmud A, Feely J. Vascular effects of amlodipine in essential hypertension. Br J Clin Pharmacol. 2004;57:684–685
  18. Morgan T, Lauri JI, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17:118–123
  19. Komai N, Ohishi M, Moriguchi A, Yanagitani Y, Jinno T, Matsumoto K, et al. Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation. Hypertens Res. 2002;25(1):5–10
  20. Rehman A, Rahman AR, Rasool AH, Naing NN. The effects of angiotensin II on pulse wave velocity in healthy humans. Int J Clin Pharmacol Ther. 2001;39(10):423–430
  21. Wilkinson I, MacCallum H, Hupperetz PC, van Thoor CJ, Cockcroft JR, Webb DJ. Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol. 2001;530:541–550
  22. Vingerhoedt NM, Gilles R, Howes JB, Griffin M, Howes LG. Haemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteers. J Renin Angiotensin Aldosterone Syst. 2003;4(4):244–248
  23. Mahmud A, Feely J. Arterial stiffness and the renin–angiotensin–aldosterone system. J Renin Angiotensin Aldosterone Syst. 2004;5(3):102–108
  24. Schmidt BM, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, et al. Rapid non-genomic effects of aldosterone on human forearm vasculature. Hypertension. 2003;42(2):156–160
  25. Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens. 2003;16(1):80–86
  26. Lacolley P, Labat C, Pujol A, Delcayre C, Benefit A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone–salt-treated rats: effects of eplerenone. Circulation. 2002;106(22):2848–2853
  27. Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens. 1997;10:1326–1334
  28. Resnick LM, Catanzaro D, Sealey JE, Laragh JH. Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin–aldosterone system. Am J Hypertens. 2004;17:203–208
  29. Mahmud A, Feely J. Aldosterone to renin ratio, arterial stiffness and the response to aldosterone antagonism in essential hypertension. Am J Hypertens. 2005;18:50–55
  30. Mahmud A, Feely J. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J Hum Hypertens. 2000;14:54–56
  31. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens. 2002;15:321–325
  32. White WB, Duprez D, St. Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, et al. Effects of the selective aldosterone antagonist eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003;41(5):1021–1026
  33. Mahmud A, Feely J. Greater reduction in arterial stiffness with low-dose polypill compared with monotherapy in hypertension. Br J Clin Pharmacol. 2005;59:631
  34. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103(7):987–992
  35. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213–1225
  36. Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N, Aggeli C, et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation. 2005;112(14):2193–2200
  37. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46(5):1118–1121
  38. Mahmud A, Feely J. Adiponectin and arterial stiffness. Am J Hypertens. 2005;18:1543–1548
  39. McNulty M, Mahmud A, Spiers J, Feely J. Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects. J Hum Hypertens. 2006;20:867–873
  40. McNulty M, Mahmud A, Feely J. Advanced glycation end products and arterial stiffness in hypertension. Am J Hypertens. 2007;20(3):242–247
  41. Zhou S, Mahmud A, Spiers JP, Feely J. Matrix metalloproteinase-9 polymorphism contributes to blood pressure and large arterial stiffness in essential hypertension. Br J Clin Pharmacol. 2006;61(5):629–630

PII: S1872-9312(07)00002-6

doi: 10.1016/j.artres.2007.03.001

Artery Research
Volume 1, Issue 1 , Pages 13-19 , June 2007

Article Tools

* Image Usage & Resolution